Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)

Authors

Alison R. Walker, The Ohio State University
Ravi Vij, Washington University School of Medicine in St. Louis
et al.

Journal

Blood Advances

Publication Date

2021

Volume

5

Issue

13

First Page

2775

Last Page

2787

Document Type

Open Access Publication

DOI

10.1182/bloodadvances.2021004233

Rights and Permissions

Alison R. Walker, Guido Marcucci, Jun Yin, William Blum, Wendy Stock, Jessica Kohlschmidt, Krzysztof Mrózek, Andrew J. Carroll, Ann-Kathrin Eisfeld, Eunice S. Wang, Sawyer Jacobson, Jonathan E. Kolitz, Mohan Thakuri, Grerk Sutamtewagul, Ravi Vij, Robert K. Stuart, John C. Byrd, Clara D. Bloomfield, Richard M. Stone, Richard A. Larson; Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance). Blood Adv 2021; 5 (13): 2775–2787. doi: https://doi.org/10.1182/bloodadvances.2021004233

Recommended Citation

Walker, Alison R.; Vij, Ravi; and al., et, "Phase 3 randomized trial of chemotherapy with or without oblimersen in older AML patients: CALGB 10201 (Alliance)." Blood Advances. 5, 13. 2775 - 2787. (2021).
https://digitalcommons.wustl.edu/open_access_pubs/10576